Antibody treatment of ulcerative colitis

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 3, 2006, Pages 353-360

  Vexler, Vladimir ^a   Woo, Jacky ^a  

^a Translational Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BASILIXIMAB; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CM T 412; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DACLIZUMAB; EPITOPE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ALPHA; MDX 1100; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; PRILIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VISILIZUMAB;

BIOLOGICAL THERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATION; DRUG HYPERSENSITIVITY; DRUG TARGETING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INFLAMMATION; LUPUS LIKE SYNDROME; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; REVIEW; TUBERCULOSIS; ULCERATIVE COLITIS;

EID: 33751262503     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.07.002     Document Type: Review

References (40)

1. Fuss I.J., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113 (2004) 1490-1497
2. Melgar S., et al. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin. Exp. Immunol. 134 (2003) 127-137
3. Cao W., et al. Production of IL-1beta, hydrogen peroxide, and nitric oxide by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis. Am. J. Physiol. Cell Physiol. 289 (2005) C1408-C1416
4. Uguccioni M., et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am. J. Path. 155 (1999) 331-336
5. van Assche G., and Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 228 (2005) G169-G174
6. Bu P., et al. Apoptosis: one of the mechanisms that maintains upresponsiveness of the intestinal mucosal immune system. J. Immunol. 166 (2001) 6399-6403
7. Brimnes J., et al. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J. Immunol. 174 (2005) 5814-5822
8. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin. Chem. 52 (2006) 171-181
9. Banks C., et al. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J. Pathol. 199 (2003) 28-35
10. Lee H.J., et al. Increased expression of MIP-1alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment. Inflamm. Bowel Dis. 11 (2005) 1070-1079
11. Rutgeerts P., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Eng. J. Med. 353 (2005) 2462-2476
12. Bradley L.M., et al. Blockade of both L-selectin and alpha4 intergrins abrogates naïve CD4 cell trafficking and response in gut-associated lymphoid organs. Int. Immunol. 10 (1998) 961-968
13. Jinno Y., et al. Infiltration of CD19(+) plasma cells with frequent labeling of Ki-67 in corticosteroid-resistant active ulcerative colitis. Virchows Arch. 448 (2006) 412-421
14. Coiffier B., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New Eng. J. Med. 346 (2002) 235-242
15. Cambridge G., et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54 (2006) 723-732
16. Jarnerot G., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
17. Armuzzi A., et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur. Rev. Med. Pharmacol. Sci. 8 (2004) 231-233
18. Baert F., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Eng. J. Med. 348 (2003) 601-608
19. Bratcher J.M., et al. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin. Drug Saf. 5 (2006) 9-16
20. Westhovens R., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 54 (2006) 1075-1086
21. Gordon F.K., et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol. Ther. 16 (2002) 699-705
22. Yousry T.A., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Eng. J. Med. 354 (2006) 924-933
23. Feagan B.G., et al. Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin. N. Engl. J. Medicine 352 (2005) 2499-2507
24. Cole M.S., et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 68 (1999) 563-571
25. Plevy S., et al. A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe, steroid refractory ulcerative colitis: results of a Phase I study. Gastroenterology 126 (2004) A-75
26. Targan SR et al. (2005) A phase 1/2 study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with iv steroids (IVSR-UC). Digestive Disease Week, 14-19 June 2005, Chicago, IL, USA (Abstract 493).
27. Woo J., et al. Visilizumab treatment of intravenous steroid refractory ulcerative colitis patients does not alter phenotype and functions of peripheral T cells. Gut 37 Suppl. 1 (2005) A173
28. Vexler V. Differential effects of visilizumab on resting and activated human T cells. Gut 37 Suppl. 1 (2005) A260
29. Sheridan J. Visilizumab, a humanized non-FcR binding anti-CD3 monoclonal antibody, causes a reduction in CXCR3+ memory T cells in vitro and inhibits CXCR3-dependent PBMC chemotaxis. Gut 53 Suppl. 1 (2004) A55
30. Bisirirska B., et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clinic Invest. 115 (2005) 2904-2913
31. Stronkhorst A., et al. CD4 antibody treatment in patients with active Crohn's disease: a phase I dose finding study. Gut 40 (1997) 320-327
32. van Assche G., et al. A pilot study on the use of humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am. J. Gastroenterol. 98 (2003) 369-376
33. Creed T.J., et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol. Ther. 18 (2003) 65-75
34. van Assche, G. et al. Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled, dose- ranging trial; Gut 10.1136/gut.2005.089854 (in press) (Currently published online: http://www.gut.bmjjournals.com/cgi/rapidpdf/gut.2005.089854v1)
35. Hanauer S., et al. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-monoclonal antibody adalimumab for the induction of remission in patients with moderate to severly active Crohn's disease. Gastroenterology 127 (2004) 332
36. Schreiber S., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
37. Ito H. Treatment of Crohn's disease with anti-IL-6 receptor antibody. J. Gastroenterol Suppl. 16 (2005) 32-34
38. Mannon P.J., et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Eng. J. Med. 351 (2004) 2069-2079
39. Hommes D.W., et al. Fontolizumab, a humanized anti-interferon-gamma antibody, demonstrates safety and potential clinical activity in patients with moderate-to-severe Crohn's disease. Gut 55 (2006) 1131-1137
40. Sidiropoulos P.I., et al. Differential drug resistance to anti-tumor necrosis factor agents in rheumatoid arthritis. Annals of the Rheumatic Diseases 65 (2006) 701-703